Emergent Biosolutions Inc. (NYSE:EBS) was up 5.2% on Wednesday . The company traded as high as $32.00 and last traded at $31.89, with a volume of 197,348 shares changing hands. The stock had previously closed at $30.30.

A number of equities research analysts have recently weighed in on EBS shares. Cowen and Company lowered shares of Emergent Biosolutions from an “outperform” rating to a “market perform” rating in a report on Wednesday, June 22nd. Singular Research cut their price target on shares of Emergent Biosolutions from $44.00 to $40.00 and set a “buy” rating on the stock in a research note on Tuesday, June 28th. Chardan Capital initiated coverage on shares of Emergent Biosolutions in a research note on Friday, April 15th. They set a “buy” rating and a $47.00 price target on the stock. Wells Fargo & Co. reiterated a “buy” rating on shares of Emergent Biosolutions in a research note on Wednesday, June 22nd. Finally, Zacks Investment Research lowered shares of Emergent Biosolutions from a “hold” rating to a “sell” rating in a research note on Tuesday, June 28th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. Emergent Biosolutions presently has a consensus rating of “Hold” and an average price target of $42.75.

The firm has a market cap of $1.27 billion and a P/E ratio of 17.00. The stock has a 50-day moving average of $35.47 and a 200 day moving average of $36.69.

Emergent Biosolutions (NYSE:EBS) last announced its earnings results on Thursday, May 5th. The biopharmaceutical company reported $0.16 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.07) by $0.23. During the same quarter in the prior year, the company earned ($0.50) EPS. The company earned $111 million during the quarter, compared to the consensus estimate of $101.83 million. The business’s quarterly revenue was up 74.5% on a year-over-year basis. On average, analysts anticipate that Emergent Biosolutions Inc. will post $1.45 earnings per share for the current fiscal year.

In other news, Director Jerome M. Hauer sold 4,700 shares of the firm’s stock in a transaction dated Thursday, May 12th. The shares were sold at an average price of $38.50, for a total transaction of $180,950.00. Following the completion of the transaction, the director now owns 18,800 shares in the company, valued at approximately $723,800. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Daniel Abdun-Nabi sold 8,699 shares of the firm’s stock in a transaction dated Wednesday, June 1st. The shares were sold at an average price of $43.74, for a total transaction of $380,494.26. Following the transaction, the chief executive officer now owns 170,966 shares of the company’s stock, valued at approximately $7,478,052.84. The disclosure for this sale can be found here.

Other institutional investors have bought and sold shares of the company. Eagle Asset Management raised its position in Emergent Biosolutions by 143.9% in the third quarter. Eagle Asset Management now owns 1,245,128 shares of the biopharmaceutical company’s stock valued at $35,472,000 after buying an additional 734,578 shares during the period. Matarin Capital Management LLC acquired a new position in Emergent Biosolutions during the fourth quarter valued at $7,953,000. Dimensional Fund Advisors LP raised its position in Emergent Biosolutions by 6.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,911,645 shares of the biopharmaceutical company’s stock valued at $76,485,000 after buying an additional 112,452 shares during the period. Bank of Montreal Can raised its position in Emergent Biosolutions by 346.9% in the fourth quarter. Bank of Montreal Can now owns 93,100 shares of the biopharmaceutical company’s stock valued at $3,725,000 after buying an additional 72,266 shares during the period. Finally, Aberdeen Asset Management PLC UK raised its position in Emergent Biosolutions by 25.2% in the fourth quarter. Aberdeen Asset Management PLC UK now owns 342,726 shares of the biopharmaceutical company’s stock valued at $10,304,000 after buying an additional 69,026 shares during the period.

Emergent BioSolutions Inc is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.